CSL324

BIOLOGICAL3 trials

Sponsors

CSL Behring

Conditions

Coronavirus Disease 2019 (COVID-19)HealthyHealthy Volunteers

Phase 1

Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects

CompletedNCT04570267

CSL BehringHealthy

Start: 2020-10-08End: 2021-12-09Updated: 2022-10-04

Effects of CSL324 in the Lung After Segmental Challenge

CompletedNCT05653713

CSL BehringHealthy Volunteers

Start: 2022-12-20End: 2023-07-21Updated: 2023-11-29

Phase 2

CSL324 in COVID-19

WithdrawnNCT04519424

CSL BehringCoronavirus Disease 2019 (COVID-19)

Start: 2020-09-30End: 2021-05-31Updated: 2020-10-14

Related Papers

Effects of anumigilimab, an anti-G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers.

2026-07-06